Addex reprices officer stock options to $0.032
Addex Therapeutics’ principal accounting officer had multiple option grants repriced to a lower $0.032 exercise price while keeping all other terms unchanged.
Rhea-AI Filing Summary
Addex Therapeutics Ltd. (ADXN) reported that its principal accounting officer, Lenaic Nathanael Teyssedou, had multiple existing stock options adjusted on September 2, 2026. Several option awards previously carrying exercise prices including $0.160, $0.053, and $0.062 per share were reported as dispositions to the issuer and corresponding acquisitions of replacement options with an exercise price of $0.032 per share. All other terms of the options, including their original exercise and expiration dates, remain unchanged, and the transactions are described as exempt under Rule 16b-6(d) and Rule 16b-3.
Positive
- None.
Negative
- None.
Insider Trade Summary
16 transactions reported
Mixed
16 txns
Insider
Teyssedou Lenaic Nathanael
Role
PRINCIPAL ACCOUNTING OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock-option (Right to Buy) F2, F1 | 37,770 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 37,770 | $0.00 | $0.00 |
| Disposition | Stock-option (Right to Buy) F2, F1 | 59,530 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 59,530 | $0.00 | $0.00 |
| Disposition | Stock-option (Right to Buy) F2, F1 | 10,000 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 10,000 | $0.00 | $0.00 |
| Disposition | Stock-option (Right to Buy) F2, F1 | 30,000 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 30,000 | $0.00 | $0.00 |
| Disposition | Stock-option (Right to Buy) F2, F1 | 65,620 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 65,620 | $0.00 | $0.00 |
| Disposition | Stock-option (Right to Buy) F2, F1 | 90,529 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 90,529 | $0.00 | $0.00 |
| Disposition | Stock-option (Right to Buy) F2, F1 | 208,974 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 208,974 | $0.00 | $0.00 |
| Disposition | Stock-option (Right to Buy) F2, F1 | 100,485 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 100,485 | $0.00 | $0.00 |
Holdings After Transaction:
Stock-option (Right to Buy) — 9,043,620 contracts (Direct)
Footnotes (2)
- F1. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
- F2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
Key Figures
New exercise price: $0.032 per share
Prior exercise price example: $0.160 per share
Largest single option block repriced: 208,974 options
+3 more
6 metrics
New exercise price
$0.032 per share
Exercise price of repriced stock options as of September 2, 2026
Prior exercise price example
$0.160 per share
One of the previous exercise prices for options repriced on September 2, 2026
Largest single option block repriced
208,974 options
Block of stock options with prior $0.053 exercise price repriced to $0.032
Another repriced option block
100,485 options
Stock-option tranche with prior $0.062 exercise price repriced to $0.032
CHF to USD exchange rate
$1.2296 per CHF 1.00
Rate used to convert the repriced exercise price into U.S. dollars
Latest grant’s expiration date
January 7, 2034
Expiration date for one repriced option grant originally exercisable from January 8, 2024
Key Terms
Disposition to issuer, Rule 16b-6(d), Rule 16b-3, Stock-option (Right to Buy), +2 more
6 terms
Disposition to issuer financial
"Several option awards were reported as a disposition to issuer and acquisition"
Rule 16b-6(d) regulatory
"transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"
Rule 16b-3 regulatory
"transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Stock-option (Right to Buy) financial
"Stock-option (Right to Buy) was the security title for each transaction"
exercise price financial
"the exercise price of the options were repriced to $0.032"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
exchange rate financial
"reflects the conversion from CHF to USD at an exchange rate"
Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.
FAQ
What did Addex Therapeutics Ltd. (ADXN) disclose about Lenaic Nathanael Teyssedou’s options?
Addex disclosed that Lenaic Nathanael Teyssedou had several existing stock options reported as dispositions and corresponding acquisitions on September 2, 2026, reflecting a repricing of those options to a new exercise price of $0.032 per share, with all other terms unchanged.
Were the Addex Therapeutics (ADXN) options newly granted or repriced?
The options were repriced. Existing stock options originally granted on dates between 2018 and 2024 with higher exercise prices were reported as disposed of to the issuer and replaced by options with an exercise price of $0.032 per share, keeping their other terms the same.
What is the new exercise price of the repriced Addex Therapeutics (ADXN) options?
The repriced stock options for Addex Therapeutics’ principal accounting officer now carry an exercise price of $0.032 per share. Footnotes state this exercise price is reported in U.S. dollars after converting from Swiss francs using a rate of $1.2296 per CHF 1.00 as of September 2, 2026.
What old exercise prices were replaced in the Addex Therapeutics (ADXN) option repricing?
The repricing replaced several previous exercise prices, including $0.160, $0.053, and $0.062 per share, with a new exercise price of $0.032 per share. The underlying options retained their original exercise and expiration dates for each grant.
Were the Addex Therapeutics (ADXN) option repricing transactions under a Rule 10b5-1 plan?
The Form 4 indicates that no Rule 10b5-1 trading plan checkbox is marked, and the footnotes do not reference any such plan. The transactions are instead described as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.
How were currency and exchange rate handled for the Addex Therapeutics (ADXN) option repricing?
The exercise price is reported in U.S. dollars and reflects a conversion from Swiss francs. The footnote states the rate used was $1.2296 per CHF 1.00 as of September 2, 2026, which was applied to present the repriced exercise amount in dollars.
AI-generated analysis. How Rhea-AI works. Not financial advice.
